Abstract:The tumor microenvironment is a complex ecosystem almost unique to each patient. Most of available therapies target tumor cells according to their molecular characteristics, angiogenesis or immune cells involved in tumor immune-surveillance. Unfortunately, only a limited number of patients benefit in the long-term of these treatments that are often associated with relapses, in spite of the remarkable progress obtained with the advent of immune checkpoint inhibitors (ICP). The presence of “hot” tumors is a determining parameter for selecting therapies targeting the patient immunity, even though some of them still do not respond to treatment. In human studies, an in-depth analysis of the organization and interactions of tumor-infiltrating immune cells has revealed the presence of an ectopic lymphoid organization termed tertiary lymphoid structures (TLS) in a large number of tumors. Their marked similarity to secondary lymphoid organs has suggested that TLS are an “anti-tumor school” and an “antibody factory” to fight malignant cells. They are effectively associated with long-term survival in most solid tumors, and their presence has been recently shown to predict response to ICP inhibitors. This review discusses the relationship between TLS and the molecular characteristics of tumors and the presence of oncogenic viruses, as well as their role when targeted therapies are used. Also, we present some aspects of TLS biology in non-tumor inflammatory diseases and discuss the putative common characteristics that they share with tumor-associated TLS. A detailed overview of the different pre-clinical models available to investigate TLS function and neogenesis is also presented. Finally, new approaches aimed at a better understanding of the role and function of TLS such as the use of spheroids and organoids and of artificial intelligence algorithms, are also discussed. In conclusion, increasing our knowledge on TLS will undoubtedly improve prognostic prediction and treatment selection in cancer patients with key consequences for the next generation immunotherapy.

Tertiary lymphoid structures and B cells: An intratumoral immunity cycle

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity

Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?

Tertiary lymphoid structures in the era of cancer immunotherapy

Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?

Tertiary Lymphoid Structure and B‑cell‑related Pathways: A Potential Target in Tumor Immunotherapy (Review)

Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer

Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy

Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies

Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer

Cellular and molecular mechanisms regulating the development of tertiary lymphoid structures in tumor

Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes

Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy

Tertiary lymphoid structures in anticancer immunity

Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer